Latest AtheroNova Inc. Stories
Anticipate Topline Data in 6-8 months IRVINE, Calif., July 30, 2014 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001. This Phase 1b trial will be a continuation of the AHRO-001...
- Exultant; jubilant; triumphant; on the high horse.
- Tipsy; slightly intoxicated.